KELOWNA, BC – The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (“The Company”, “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, today announced two agreements with PMI Mexico, a subsidiary of Merger Group , one of the Mexican government’s leading drug suppliers. Under the first agreement, Valens will supply CBD for PMI’s pharmacokinetic phase (PK) medical trials, which focus on anti-inflammatory applications of medical-grade nano-water emulsified CBD oil. The clinical trial has already been approved by the Mexican Medical Ethics Board. The clinical trial, which will begin once Valens’ shipments arrive in the first quarter of 2022, will be conducted at private hospitals in Mexico. At the end of the trial, Valens will be the only global manufacturer and distributor in collaboration with PMI.
Under the second agreement, Valens will manufacture and distribute Predilife® products with and without CBD infusion worldwide, while PMI will be responsible for distributing Predilife® products in Mexico. Predilife is an agave-based prebiotic powder that has been sent as a “drug master file” (DMF) to the FDA. Valens will manufacture the products at its Green Roads facility in Florida, where it will be infused with CBD as needed and will then be packaged and distributed through Valens third-party supplier channels in Asia, the US, Latin America and Mexico.The formulation will be offered in both powdered and liquid sachets, initially for human consumption. , with animal variations planned for the second half of 2022.
“The relationship we have built with PMI Mexico marks an important milestone for Valens’ international expansion and the beginning of our strategy for Central and Latin America,” said Tyler Robson, CEO, President and Co-Founder of The Valens. Company. “Predilife has a significant and unique versatility in terms of scope and market potential, as it can be consumed with CBD or without infusion. This allows for a barrier-free distribution of the product regardless of local cannabis regulations, providing “This agreement diversifies our global markets. This agreement diversifies our global strategy and increases our revenue through creative, non-traditional strategies that separate us from our peers.”
Dr. Gustavo Bustillo, Scientific Director of PMI, said: “At Valens we found a technology partner capable of providing us with not only the required quality but also the technical support and documentation needed to comply with pharmaceutical regulations. We look forward to starting our business relationship and seeing it expand globally over the next few years. “
In Valens, it’s personal.
About The Valens Company
The Valens Company is a world leader in the development and end-to-end manufacturing of innovative cannabinoid-based products. The Valens Company focuses on being the partner of choice for major Canadian and international cannabis brands, offering the best in-class services such as CO2, ethanol, hydrocarbons, terpene extraction and solvent-free, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party mining company in Canada, with an annual capacity of 425,000 kg of dry cannabis and hemp biomass at our specifically built facility in Kelowna, British Columbia, which is in the process of being converted. in the European Union (EU) Good Manufacturing Practices. compatible (GMP). Valens currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and spray pens, as well as beverages, concentrates, topicals, groceries, injectables, natural products for health and has a solid pipeline of new generation products under development for future release. Finally, Valens Labs, a wholly owned subsidiary of The Valens Company, is an ISO 17025 licensed cannabis testing laboratory licensed by Health Canada that offers industry leading analytical services and has partnered with Thermo Fisher Scientific to develop a center of excellence in plant-based science. For more information, visit https://thevalenscompany.com. The Valens Company investor platform can be found specifically at https://thevalenscompany.com/investors/.
About Merger Group
Newark, Delaware-based Merger Group is a pioneer in the development of drugs and supplements with more than 20 years of experience in the pharmaceutical industry. Merger Group is dedicated to the research, innovation and development of both medicines and natural and herbal products that can help progress the lifestyle of its users by improving their health and well-being. PMI Mexico, a division of Merger Group, is a subsidiary dedicated to research, clinical studies, review and integration of technical documentation for obtaining health records, logistics coordination and import permits.
